Efficacy and tolerability of bevacizumab in patients with severe Covid-19

On the basis of Covid-19-induced pulmonary pathological and vascular changes, we hypothesize that the anti-vascular endothelial growth factor (VEGF) drug bevacizumab might be beneficial for treating Covid-19 patients. From Feb 15 to April 5, 2020, we conducted a single-arm trial (NCT04275414) and re...

Descripción completa

Detalles Bibliográficos
Autores principales: Pang, Jiaojiao, Xu, Feng, Aondio, Gianmarco, Li, Yu, Fumagalli, Alberto, Lu, Ming, Valmadre, Giuseppe, Wei, Jie, Bian, Yuan, Canesi, Margherita, Damiani, Giovanni, Zhang, Yuan, Yu, Dexin, Chen, Jun, Ji, Xiang, Sui, Wenhai, Wang, Bailu, Wu, Shuo, Kovacs, Attila, Revera, Miriam, Wang, Hao, Jing, Xu, Zhang, Ying, Chen, Yuguo, Cao, Yihai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7864918/
https://www.ncbi.nlm.nih.gov/pubmed/33547300
http://dx.doi.org/10.1038/s41467-021-21085-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7864918/
https://www.ncbi.nlm.nih.gov/pubmed/33547300
http://dx.doi.org/10.1038/s41467-021-21085-8

Ejemplares similares